Nutritional and health experts say that having it to start the day has major benefits including blood sugar levels, ...

The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein(a) ...

Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more, making it the focus of many heart health campaigns.

Eli Lilly's muvalaplin Phase 2 trial showed significant Lp(a) reduction, meeting primary and secondary endpoints with ...

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

A troubled Orleans County nursing home – already in the crosshairs of the state attorney general – is facing more than ...

A study testing a new nasal spray form of the medication bumetanide, a commonly prescribed diuretic, was found to be as safe and well-tolerated (meaning with no significant nasal irritation) in ...